Anthony Kevin Webb
Directeur/Membre du Conseil chez The Medicines Evaluation Unit Ltd.
Provenance du réseau au premier degré de Anthony Kevin Webb
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
North West Lung Centre
 North West Lung Centre Medical/Nursing ServicesHealth Services North West Lung Centre provides services related to other human health activities.
8
| Non-Profit Organization | Medical/Nursing Services | 8 |
The Medicines Evaluation Unit Ltd.
 The Medicines Evaluation Unit Ltd. Miscellaneous Commercial ServicesCommercial Services The Medicines Evaluation Unit Ltd. offers clinical trial solutions. It provides clinical trials and early phase exploratory studies in the pharmaceutical, scientific and clinical sectors. The firm specializes in performing clinical trials in respiratory and inflammatory medicine and related areas as well as conducting healthy volunteer, bioequivalence and SAD/MAD studies. The company is headquartered in Manchester, the United Kingdom.
4
| Subsidiary | Miscellaneous Commercial Services | 4 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Anthony Kevin Webb via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
Reacta Biotech Ltd.
 Reacta Biotech Ltd. Miscellaneous Commercial ServicesCommercial Services Reacta Biotech Ltd. engages in a biotechnology company. It develops, manufactures, and commercializes oral food challenge materials to pharmaceuticals standards of Good Manufacturing Practice (GMP). The company was founded by Clare Mills, Ashley Woodcock, and Peter McPartland in June 2013 and is headquartered in Deeside, the United Kingdom. | Miscellaneous Commercial Services | Founder | |
| Axalbion SA | Chairman | ||
Axalbion Therapeutics Ltd.
 Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt. | Biotechnology | Chairman |
Statistiques
Internationale
| Royaume-Uni | 3 |
| Suisse | 2 |
Sectorielle
| Commercial Services | 2 |
| Health Technology | 2 |
Opérationnelle
| Director/Board Member | 11 |
| Chairman | 4 |
| Chief Operating Officer | 1 |
| Corporate Secretary | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Relations les plus connectées
- Bourse
- Insiders
- Anthony Kevin Webb
- Connexions Sociétés
